Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: A prospective registry

JACC: Cardiovascular Interventions

Volumn 3, Issue 6, 2010, Pages 648-656

  El Ghannudi, Soraya ^a   Ohlmann, Patrick ^a   Meyer, Nicolas ^b   Wiesel, Marie Louise ^c   Radulescu, Bogdan ^a   Chauvin, Michel ^a   Bareiss, Pierre ^a   Gachet, Christian ^c   Morel, Olivier ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^c INSERM   (France)

Author keywords

acute coronary syndrome; clopidogrel resistance; percutaneous coronary intervention; platelet; thienopyridines

Indexed keywords

ADENOSINE DIPHOSPHATE; C REACTIVE PROTEIN; CLOPIDOGREL; PURINERGIC P2Y12 RECEPTOR; VASODILATOR STIMULATED PHOSPHOPROTEIN; ACTIN BINDING PROTEIN; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; DRUG DERIVATIVE; PHOSPHOPROTEIN; PURINERGIC P2 RECEPTOR; TICLOPIDINE; VASODILATOR-STIMULATED PHOSPHOPROTEIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONFIDENCE INTERVAL; CREATININE CLEARANCE; DRUG ELUTING STENT; FLOW CYTOMETRY; FOLLOW UP; HAZARD RATIO; HEART DEATH; HIGH RISK POPULATION; HUMAN; IMPLANTATION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; STENT THROMBOSIS; THROMBOCYTE; THROMBOCYTE ACTIVATION; TRANSLUMINAL CORONARY ANGIOPLASTY; BLOOD; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; FEMALE; FRANCE; INSTRUMENTATION; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PHOSPHORYLATION; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROSTHESIS; REGISTER; RISK ASSESSMENT; RISK FACTOR; THROMBOSIS; TIME; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; CELL ADHESION MOLECULES; DRUG RESISTANCE; DRUG-ELUTING STENTS; FEMALE; FLOW CYTOMETRY; FRANCE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; PHOSPHOPROTEINS; PHOSPHORYLATION; PLATELET AGGREGATION INHIBITORS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; RECEPTORS, PURINERGIC P2; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; THROMBOSIS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 78049417758     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2010.03.003     Document Type: Article

References (32)

1. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004;24:1980-7.
2. Gachet C. P2 receptors, platelet function and pharmacological implications. Thromb Haemost 2008;99:466-72.
3. Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005;3:85-92. (Pubitemid 41647119)
4. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009;373:309-17.
5. Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008;51:1925-34.
6. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-62.
7. Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006;48:1742-50.
8. Cuisset T, Frere C, Quilici J, et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006;4:542-9.
9. Bonello L, Camoin-Jau L, Armero S, et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009;103:5-10.
10. Aleil B, Jacquemin L, De Poli F, et al. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. J Am Coll Cardiol Intv 2008;1:631-8.
11. Cuisset T, Frere C, Quilici J, Alessi MC, Bonnet JL. Adjusting clopidogrel loading doses according to vasodilator-stimulated phospho-protein index: on time, too early, or too late? J Am Coll Cardiol 2008;52:790-1, reply 791-2.
12. Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008;51:1404-11.
13. Morel O, Faure A, Ohlmann P, et al. Impaired platelet responsiveness to clopidogrel identified by flow cytometric vasodilator-stimulated phosphoprotein (VASP) phosphorylation in patients with subacute stent thrombosis. Thromb Haemost 2007;98:896-9.
14. Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to thienopy-ridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003;59:295-302.
15. Blindt R, Stellbrink K, de Taeye A, et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 2007;98:1329-34.
16. Gachet C, Aleil B. Testing antiplatelet therapy. Eur Heart J Suppl 2008;10 Suppl A:A28-34.
17. Bonello L, Paganelli F, Arpin-Bornet M, et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007;5:1630-6.
18. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel. Relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009;119:2553-60.
19. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007;154:221-31.
20. Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009;119:237-42.
21. Paniccia R, Antonucci E, Gori AM, et al. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 2007;5:1839-47.
22. Schumacher WA, Bostwick JS, Ogletree ML, et al. Biomarker optimization to track the antithrombotic and hemostatic effects of clopi-dogrel in rats. J Pharmacol Exp Ther 2007;322:369-77.
23. Lagerqvist B, Carlsson J, Frobert O, et al. Stent thrombosis in Sweden: a report from the Swedish coronary angiography and angioplasty registry. Circ Cardiovasc Interv 2009;2:401-8.
24. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007;356:1009-19.
25. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007;297:159-68.
26. Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008;299:532-9.
27. Angiolillo DJ. Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care 2009;32:531-40.
28. Ang L, Palakodeti V, Khalid A, et al. Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. J Am Coll Cardiol 2008;52:1052-9.
29. Angiolillo DJ, Bernardo E, Sabate M, et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2007;50:1541-7.
30. Erlinge D, Varenhorst C, Braun OO, et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol 2008;52:1968-77.
31. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? J Invasive Cardiol 2004;16:169-74.
32. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15.